oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial Oral Semaglutide Lowers Cardiovascular Events

These include: Nausea and vomiting Diarrhoea or constipation Abdominal discomfort or bloating Reduced appetite These symptoms usually resolve within 24 weeks after stopping treatment, though the timeline varies individually

Which nitrosamines are most relevant to Azithromycin API

[1] Do not use Zepbound if it has been frozen

As a GLP-1 agonist medication, semaglutide mimics GLP-1 a natural hormone released by your pancreas after you eat

When to Speak with Your GP About Unexpected Weight Gain Patients should contact their GP or diabetes specialist nurse if they experience unexpected weight gain whilst taking Ozempic, particularly under certain circumstances that may indicate underlying medical issues requiring investigation